Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24713838 | 0.89 | PIK3CB (0.60) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13759893 | 0.85 | PIK3CB (0.68) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752235 | 0.82 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL3201554 | 0.82 | PIK3CB (0.64) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24713672 | 0.81 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL13752218 | 0.81 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL5870441 | 0.81 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4348681 | 0.80 | PIK3CB (0.60) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24713661 | 0.79 | PIK3CB (0.68) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL5870416 | 0.79 | PIK3CB (0.59) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117615763-A | Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof | 健道生物医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PIK3CB 14/4885PIK3CD 13/4885PIK3CA 1/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PIK3CB 14/4885PIK3CD 13/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.